The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

The World Health Organization has tracked a new COVID-19 variant that has emerged across multiple region. Amid this, the Food ...

From eligibility to dosage and future rollout, here’s what you need to know about the FDA’s latest vaccine approval.

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.

Approval was based on data from the Phase III NextCOVE trial, which demonstrated that mNEXSPIKE met non-inferiority criteria ...

Moderna said mNEXSPIKE was approved by the FDA for use in adults aged 65 and up, as well as some individuals aged 12 to 64.

A Phase III trial demonstrated mNEXSPIKE’s non-inferior efficacy compared with Moderna’s original COVID vaccine, Spikevax.

Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID ...

Moderna's mNexspike COVID vaccine approved by FDA for older adults and at-risk groups after Phase 3 trial shows improved ...

FDA approves Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk groups Phase 3 trial shows mNEXSPIKE outperforms original ...

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing ...

Shares of Moderna climbed Monday after the Food and Drug Administration approved a new COVID-19 vaccine from the drugmaker.